166 related articles for article (PubMed ID: 22760213)
1. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.
Decker T; Fischer G; Bücke W; Bücke P; Stotz F; Grüneberger A; Gropp-Meier M; Wiedemann G; Pfeiffer C; Peschel C; Götze K
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1945-50. PubMed ID: 22760213
[TBL] [Abstract][Full Text] [Related]
2. A flow cytometry based assay for the enumeration of regulatory T cells in whole blood.
Hardy MY; Vari F; Rossetti T; Hart DN; Prue RL
J Immunol Methods; 2013 Apr; 390(1-2):121-6. PubMed ID: 22824721
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
[TBL] [Abstract][Full Text] [Related]
4. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of Treg cell frequency in acute myeloid leukemia.
Yang W; Xu Y
Int J Hematol; 2013 Nov; 98(5):558-62. PubMed ID: 24142765
[TBL] [Abstract][Full Text] [Related]
6. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Perez SA; Karamouzis MV; Skarlos DV; Ardavanis A; Sotiriadou NN; Iliopoulou EG; Salagianni ML; Orphanos G; Baxevanis CN; Rigatos G; Papamichail M
Clin Cancer Res; 2007 May; 13(9):2714-21. PubMed ID: 17473204
[TBL] [Abstract][Full Text] [Related]
7. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.
Longhi MS; Meda F; Wang P; Samyn M; Mieli-Vergani G; Vergani D; Ma Y
Hepatology; 2008 Feb; 47(2):581-91. PubMed ID: 18220288
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
10. Immunological monitoring of extracorporeal photopheresis after heart transplantation.
Dieterlen MT; Bittner HB; Pierzchalski A; Dhein S; Mohr FW; Barten MJ
Clin Exp Immunol; 2014 Apr; 176(1):120-8. PubMed ID: 24329680
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
[TBL] [Abstract][Full Text] [Related]
12. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway.
Liberal R; Grant CR; Holder BS; Ma Y; Mieli-Vergani G; Vergani D; Longhi MS
Hepatology; 2012 Aug; 56(2):677-86. PubMed ID: 22371007
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia.
Gómez-Martín D; Díaz-Zamudio M; Vanoye G; Crispín JC; Alcocer-Varela J
Clin Exp Immunol; 2011 Apr; 164(1):17-25. PubMed ID: 21235538
[TBL] [Abstract][Full Text] [Related]
14. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
[TBL] [Abstract][Full Text] [Related]
15. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer.
Horlock C; Stott B; Dyson PJ; Morishita M; Coombes RC; Savage P; Stebbing J
Br J Cancer; 2009 Apr; 100(7):1061-7. PubMed ID: 19277040
[TBL] [Abstract][Full Text] [Related]
16. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
17. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
[TBL] [Abstract][Full Text] [Related]
18. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.
Bailur JK; Gueckel B; Derhovanessian E; Pawelec G
Breast Cancer Res; 2015 Mar; 17(1):34. PubMed ID: 25849846
[TBL] [Abstract][Full Text] [Related]
19. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Rech AJ; Mick R; Martin S; Recio A; Aqui NA; Powell DJ; Colligon TA; Trosko JA; Leinbach LI; Pletcher CH; Tweed CK; DeMichele A; Fox KR; Domchek SM; Riley JL; Vonderheide RH
Sci Transl Med; 2012 May; 4(134):134ra62. PubMed ID: 22593175
[TBL] [Abstract][Full Text] [Related]
20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
